Esperion Therapeutics (Nasdaq: ESPR) (Esperion), a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies, and ARCHIMED, a leading investment firm focused exclusively on healthcare industries, have announced that they have entered into a definitive agreement under which funds managed by ARCHIMED will acquire Esperion in a transaction valued at up to approximately US$1.1 billion in total equity value (including a non-tradeable contingent value right (CVR) tied to the achievement of certain commercial-based milestones).
Latham & Watkins LLP advised Centerview Partners in the transaction with a corporate team led by New York partners Ian Nussbaum and Charles Ruck, with associate Patrick O’Neal. Advice was also provided on finance matters by New York partner Emily Johnson, with associate Jenny Lyubomudrova; and on litigation matters by New York partner Sarah Lightdale.
